These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 23259667)
1. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688 [TBL] [Abstract][Full Text] [Related]
3. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108 [TBL] [Abstract][Full Text] [Related]
4. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166 [TBL] [Abstract][Full Text] [Related]
5. Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients. Gilje B; Nordgård O; Tjensvoll K; Borgen E; Synnestvedt M; Smaaland R; Naume B BMC Cancer; 2014 Jul; 14():514. PubMed ID: 25023626 [TBL] [Abstract][Full Text] [Related]
6. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387 [TBL] [Abstract][Full Text] [Related]
7. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892 [TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation. Takeyama H; Shimada T; Kinoshita S; Uchida K Ann Surg Oncol; 2017 May; 24(5):1227-1233. PubMed ID: 27909824 [TBL] [Abstract][Full Text] [Related]
11. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505 [TBL] [Abstract][Full Text] [Related]
12. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome. Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230 [TBL] [Abstract][Full Text] [Related]
13. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181 [TBL] [Abstract][Full Text] [Related]
14. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396 [TBL] [Abstract][Full Text] [Related]
15. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788 [TBL] [Abstract][Full Text] [Related]
16. Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer. Gruber I; Fehm T; Taran FA; Wallwiener M; Hahn M; Wallwiener D; Krawzyck N; Hoffmann J; Hartkopf AD Breast Cancer Res Treat; 2014 Apr; 144(2):353-60. PubMed ID: 24554386 [TBL] [Abstract][Full Text] [Related]
17. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322 [TBL] [Abstract][Full Text] [Related]
18. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy. Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142 [TBL] [Abstract][Full Text] [Related]
19. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Aft R; Naughton M; Trinkaus K; Watson M; Ylagan L; Chavez-MacGregor M; Zhai J; Kuo S; Shannon W; Diemer K; Herrmann V; Dietz J; Ali A; Ellis M; Weiss P; Eberlein T; Ma C; Fracasso PM; Zoberi I; Taylor M; Gillanders W; Pluard T; Mortimer J; Weilbaecher K Lancet Oncol; 2010 May; 11(5):421-8. PubMed ID: 20362507 [TBL] [Abstract][Full Text] [Related]
20. Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis? Chebouti I; Blassl C; Wimberger P; Neubauer H; Fehm T; Kimmig R; Kasimir-Bauer S Oncotarget; 2016 May; 7(18):26454-64. PubMed ID: 27049920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]